Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Treatment of low-risk myelodysplastic syndromes

    ... is performed on the basis of IPSS-R, endogenous erythropoietin levels, and transfusion independence . Doses and ...

    Research Article last updated 01/26/2017 - 10:42am.

  2. MDS Follows Two Misdiagnoses

    ... as relatively low risk. I have been treated with erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , ...

    Patient Chronicle last updated 12/27/2016 - 7:23am.

  3. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis

    ... response duration range was 12-51+ months. Patients with erythropoietin (EPO) <100 iu/l had 35% [95% confidence interval (CI): ...

    Research Article last updated 06/23/2016 - 9:14am.

  4. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... were observed in patients with lower baseline endogenous erythropoietin ≤ 500 mU/mL (34.0% v 15.5% for > 500 mU/mL). At week 12, ...

    Research Article last updated 07/18/2016 - 10:30am.

  5. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes

    ... National Comprehensive Cancer Network guidelines: serum erythropoietin determination before ESA initiation, ... the observation period, with increased rates of serum erythropoietin levels, but declined in the other two guidelines. ...

    Research Article last updated 01/20/2015 - 1:05pm.

  6. Eltrombopag in aplastic anemia

    ... granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) have not improved outcome. A recent trial has shown ...

    Research Article last updated 03/02/2015 - 12:51pm.

  7. Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative

    ... and classification of MDS and in the documentation of erythropoietin levels. Improvements related to patient communication and ...

    Research Article last updated 02/08/2013 - 7:53am.

  8. Personalized medicine for MDS

    ... MDS and anemia who have a low (<500 U/L) erythropoietin level as well as low transfusion requirement.  Most ...

    Research Review last updated 05/02/2016 - 9:44am.

  9. MEDALIST Trial

    ... ESA regimen must have been either recombinant human erythropoietin (rHu EPO) > 40,000 IU/wk for at least 8 doses or ... low chance of response to ESA base on endogenous serum erythropoietin level > 200 U/L for subjects not previously treated with ESAs ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  10. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... or lenalidomide . The recombinant human erythropoietin (rHuEPO) erythropoiesis-stimulating agents, epoetin and ...

    Research Article last updated 03/04/2015 - 10:20am.